TIL Therapies market Analysis and Trends by 2022-2035

Owing to their tumor-killing capability and therapeutic superiority to conventional therapies, TIL-based therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global TIL-based Therapy Market (2nd Edition), 2023-2035.”

The study features an in-depth analysis of key drivers and trends related to this domain. Amongst other elements, the report includes:
 A detailed assessment of the current market landscape of TIL-based therapies.
 A detailed analysis of completed, ongoing and planned clinical studies related to TIL-based therapies.
 An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to TIL-based therapies.
 Elaborate profiles of mid- to late-stage clinical products (phase I/II or above).
 An analysis of various type of partnership that have been inked between several stakeholders in the domain of TIL therapies.
 An analysis of the investments that have been made into companies that have proprietary TIL-based products / technologies.
 An in-depth analysis of patents related to TIL-based therapies, filed / granted till 2022.
 A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
 An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
 Elaborate profiles of the several leading players in the domain of TCR cell therapies.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
 Target Indication(s)
 Melanoma
 Head and Neck Carcinoma
 Chronic Lymphocytic Leukemia
 Sarcoma
 Hepatocellular Carcinoma
 Breast Cancer
 Acute Myeloid Leukemia
 Cervical Carcinoma

 Key Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information (if available), details about TIL-based product(s), such as information on status of development, technology portfolio (if available), recent developments related to TIL-based therapies and manufacturing capabilities of the players.

 Cellectis
 Cellular Biomedicine Group
 Iovance Biotherapeutics
 Lytix Biopharma
 Phio Pharmaceuticals

To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/til-therapie


You may also be interested in the following titles:
Lab Automation Market

Cannabis Testing Market


You may also like to learn what our experts are sharing in Roots educational series:
Genotoxicity Testing: Unlocking the Future Safety Assessment Opportunities

Adeno-Associated Viral Vectors: Unlocking the Future Opportunities


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

#til-basedtherapies #tumorinfiltratinglymphocytereceptor #til #marketresearch #marketinsights